PepGen 2025 FREEDOM Trial Data Impresses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy PEPG?
"2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing correction in DM1, reinforced our conviction in PGN-EDODM1 as a potential best-in-class treatment, and further demonstrated the differentiated potential of our EDO platform," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "After a single dose, we observed robust target engagement beginning at the lowest dose of 5 mg/kg - a finding that exceeded our expectations and underscored the potency of our drug candidate. PGN-EDODM1 was generally well-tolerated across doses, and based on the totality of FREEDOM data, we believe that doses of 10 mg/kg could potentially offer a best-in-class treatment option for people living with this serious disease."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 6.760
Low
3.00
Averages
11.50
High
20.00
Current: 6.760
Low
3.00
Averages
11.50
High
20.00
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PepGen Reports Q4 2025 Earnings Beat with Strong Cash Position
- Earnings Beat: PepGen's Q4 2025 report reveals a GAAP EPS of -$0.27, surpassing expectations by $0.12, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company holds $148.5 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years.
- Funding Outlook: Based on current operational plans, PepGen believes its existing cash and equivalents will sufficiently fund operations into the second half of 2027, reflecting a solid financial position.
- Increased Market Attention: The earnings report has heightened market interest in PepGen, boosting investor confidence in its growth potential, which may positively influence the stock price.
See More
PepGen Shares Drop After FDA Partially Halts Clinical Trial
- FDA Clinical Hold: PepGen's PGN-EDODM1 trial targeting myotonic dystrophy type 1 faces a partial clinical hold from the FDA due to concerns over submitted pharmacology and toxicology studies, potentially impacting the company's future R&D efforts.
- Trial Phase Impact: The hold affects the FREEDOM2-DM1 Phase 2 trial, and while the Phase 1 FREEDOM study data remains unchallenged, this decision may lead to delays in clinical progress, thereby affecting investor confidence.
- Data Submission Commitment: PepGen has committed to submitting additional analyses to the FDA, including recently unblinded FREEDOM data, indicating the company's dedication to addressing FDA inquiries swiftly to restore trial progress and maintain market position.
- Market Reaction: Following the FDA's announcement of the partial hold, PepGen shares continued to decline in premarket trading, reflecting market unease regarding the company's clinical trial outlook, which could negatively impact its financing and future growth.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
PepGen Faces FDA Partial Hold on FREEDOM2 Trial Amid Regulatory Concerns
- FDA Partial Hold: The U.S. FDA has placed PepGen's FREEDOM2-DM1 trial on a partial clinical hold due to concerns regarding preclinical pharmacology and toxicology studies, which may hinder the company's future clinical progress and investor confidence.
- Shift in Research Focus: In May 2025, PepGen voluntarily discontinued the development of PGN-EDO51, redirecting its efforts towards myotonic dystrophy type 1 (DM1), a strategic shift that could impact its market positioning and allocation of R&D resources.
- International Trial Approval: Despite facing challenges from the FDA, PepGen has received regulatory clearance to initiate the FREEDOM2 study in South Korea, Australia, and New Zealand, indicating potential for expansion in global markets.
- Declining Stock Performance: PepGen shares fell 14.20% during premarket trading to $5.80, significantly below its 20-day and 100-day simple moving averages, reflecting a bearish outlook from the market regarding its future developments.
See More
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
See More
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.
See More
PepGen Reports Q4 2025 Earnings Beat with Strong Cash Position
- Earnings Beat: PepGen's Q4 2025 report reveals a GAAP EPS of -$0.27, surpassing expectations by $0.12, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company holds $148.5 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years.
- Funding Outlook: Based on current operational plans, PepGen believes its existing cash and equivalents will sufficiently fund operations into the second half of 2027, reflecting a solid financial position.
- Increased Market Attention: The earnings report has heightened market interest in PepGen, boosting investor confidence in its growth potential, which may positively influence the stock price.
See More
PepGen Shares Drop After FDA Partially Halts Clinical Trial
- FDA Clinical Hold: PepGen's PGN-EDODM1 trial targeting myotonic dystrophy type 1 faces a partial clinical hold from the FDA due to concerns over submitted pharmacology and toxicology studies, potentially impacting the company's future R&D efforts.
- Trial Phase Impact: The hold affects the FREEDOM2-DM1 Phase 2 trial, and while the Phase 1 FREEDOM study data remains unchallenged, this decision may lead to delays in clinical progress, thereby affecting investor confidence.
- Data Submission Commitment: PepGen has committed to submitting additional analyses to the FDA, including recently unblinded FREEDOM data, indicating the company's dedication to addressing FDA inquiries swiftly to restore trial progress and maintain market position.
- Market Reaction: Following the FDA's announcement of the partial hold, PepGen shares continued to decline in premarket trading, reflecting market unease regarding the company's clinical trial outlook, which could negatively impact its financing and future growth.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
PepGen Faces FDA Partial Hold on FREEDOM2 Trial Amid Regulatory Concerns
- FDA Partial Hold: The U.S. FDA has placed PepGen's FREEDOM2-DM1 trial on a partial clinical hold due to concerns regarding preclinical pharmacology and toxicology studies, which may hinder the company's future clinical progress and investor confidence.
- Shift in Research Focus: In May 2025, PepGen voluntarily discontinued the development of PGN-EDO51, redirecting its efforts towards myotonic dystrophy type 1 (DM1), a strategic shift that could impact its market positioning and allocation of R&D resources.
- International Trial Approval: Despite facing challenges from the FDA, PepGen has received regulatory clearance to initiate the FREEDOM2 study in South Korea, Australia, and New Zealand, indicating potential for expansion in global markets.
- Declining Stock Performance: PepGen shares fell 14.20% during premarket trading to $5.80, significantly below its 20-day and 100-day simple moving averages, reflecting a bearish outlook from the market regarding its future developments.
See More
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
See More
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.
See More
